From their presentation 1/4 2016 after changing to blood bourne target. Seems to me they changed because they perceve easier path to clinical trial, and blood bourne easier to reach than tumors as per below. It makes sense and i understand the change, but i dint think it was because they mastered one area and wanted to show they could master others as well, it was because they recognised the difficulty in sink effect if they were serious about moving from mouse model to real,significant human trials. At least that is how i arrived at my view, which obviously could be wrong
Phylogica’s Pipeline focussed on blood cancers
§ Confirmed ability to address unmet need and establish fast and efficient path to clinical trial
§ Blood cancers considered easier to access than solid tumours.
PYC Price at posting:
1.4¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)